CorMedix (CRMD) Misses Q4 EPS by 69c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.16, $0.69 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.48 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• H.C. Wainwright Reiterates Buy Rating on US GoldMining Inc. (USGO)
• United States Oil Fund (USO) call put ratio 1 call to 1.2 puts as WTI crude trends lower